BTL-slo

Drug Profile

BTL-slo

Alternative Names: BTL slo; BTL-slo/stcf

Latest Information Update: 12 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Beech Tree Labs
  • Class Exotoxins; Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Chronic obstructive pulmonary disease; Joint disorders

Most Recent Events

  • 08 Sep 2017 Beech Tree Labs has patent protection for BTL-slo/stcf for Chronic obstructive pulmonary disease in USA, with corresponding pending applications in other regions (Beech Tree Labs website, September 2017).
  • 08 Sep 2017 Preclinical trials in Chronic obstructive pulmonary disease in USA (unspecified route) (Beech Tree Labs pipeline, September 2017)
  • 08 Sep 2017 Preclinical trials in Joint disorders in USA (IV) (Beech Tree Labs pipeline, September 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top